

REMARKS

Amendment of the specification by substitution of the attached sequence listing is respectfully requested. The substitute sequence listing is provided in reply to the Notice to Comply, a response to which is currently being filed. The substitute sequence listing contains the same information as the sequence filed with the application papers but an amended SEQ. ID NO. 1 and newly added SEQ ID NO. 26. SEQ ID NO. 1 as originally filed contain the nucleotide and amino acid sequence of melanoma antigen. By this amendment, SEQ ID NO. 1 has been divided between the nucleotide sequence (SEQ ID NO. 26) and the amino acid sequence (SEQ ID NO. 1). The sequence listing also has been amended to conform to the trilateral format.

The nucleotide sequence encoding the natural epitope of human melanoma antigen MART-1 is fully disclosed in SEQ ID NO. 1. See, e.g., page 5, lines 23-28, disclosing the location of the native peptide sequence. Thus, no new matter is added by this preliminary amendment and entry thereof is respectfully requested.

In the unlikely event that the transmittal letter is separated from this document and/or the Patent Office determines that an extension and/or other relief is required, Applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 50-1189**, referencing billing reference **19442-7231**. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Date: June 4, 2002

By:


Antoinette F. Konski

Reg. No. 34,202

McCutchen, Doyle, Brown & Enersen
Three Embarcadero Center, Suite 1800
San Francisco, CA 94111
Telephone: (650) 849-4950
Facsimile: (650) 849-4800